Read by QxMD icon Read


Sakina Mhaouty-Kodja, Lydie Naulé, Daphne Capela
Sexual behavior constitutes a chain of behavioral responses beginning with courtship and leading to copulation. These responses, which are exhibited in a sexually dimorphic manner by the two partners, are tightly regulated by sex steroid hormones as early as the perinatal period. Hormonal changes or exposure to exogenous factors exhibiting hormone-mimetic activities such as endocrine disrupting compounds (EDC) can therefore interfere with their expression. Here we review the experimental studies in rodents performed to address the potential effects of exposure to EDC on sexual behavior and underlying mechanisms, with a particular attention to molecules with estrogenic and/or anti-androgenic activities...
October 16, 2018: Neuroendocrinology
Zuzana Toušová, Branislav Vrana, Marie Smutná, Jiří Novák, Veronika Klučárová, Roman Grabic, Jaroslav Slobodník, John Paul Giesy, Klára Hilscherová
Complex mixtures of contaminants from multiple sources, including agriculture, industry or wastewater enter aquatic environments and might pose hazards or risks to humans or wildlife. Targeted analyses of a few priority substances provide limited information about water quality. In this study, a combined chemical and effect screening of water quality in the River Bosna, in Bosnia and Herzegovina was carried out, with focus on occurrence and effects of contaminants of emerging concern. Chemicals in water were sampled at 10 sites along the Bosna River by use of passive sampling...
February 10, 2019: Science of the Total Environment
Guy T'Sjoen, Jon Arcelus, Louis Gooren, Daniel T Klink, Vin Tangpricha
Gender affirming treatment for transgender people requires a multidisciplinary approach in which endocrinologists play a crucial role. The aim of this paper is to review recent data on hormonal treatment of this population and its effect on physical, psychological and mental health. The Endocrine Society guidelines for transgender women include estrogens in combination with androgen lowering medications. Feminizing treatment with estrogens and anti-androgens has desired physical changes, such as enhanced breast growth, reduction of facial and body hair growth and fat redistribution in a female pattern...
October 10, 2018: Endocrine Reviews
Clément Draghi, Fabrice Denis, Alain Tolédano, Christophe Letellier
Adenocarcinoma is the most frequent cancer affecting the prostate walnut-size gland in the male reproductive system. Such cancer may have a very slow progression or may be associated with a "dark prognosis" when tumor cells are spreading very quickly. Prostate cancers have the particular properties to be marked by the level of prostate specific antigen (PSA) in blood which allows to follow its evolution. At least in its first phase, prostate adenocarcinoma is most often hormone-dependent and, consequently, hormone therapy is a possible treatment...
October 4, 2018: Journal of Theoretical Biology
Khalid N Al-Zahrani, David P Cook, Barbara C Vanderhyden, Luc A Sabourin
The Androgen Receptor (AR) has recently garnered a lot of attention as a potential biomarker and therapeutic target in hormone-dependent cancers, including breast cancer. However, several inconsistencies exist within the literature as to which subtypes of breast cancer express AR or whether it can be used to define its own unique subtype. Here, we analyze 1246 invasive breast cancer samples from the Cancer Genome Atlas and show that human breast cancers that have been subtyped based on their HER2, ESR1, or PGR expression contain four clusters of genes that are differentially expressed across all subtypes...
September 7, 2018: Oncotarget
Ling Cai, Yi-Hsuan Tsai, Ping Wang, Jun Wang, Dongxu Li, Huitao Fan, Yilin Zhao, Rohan Bareja, Rui Lu, Elizabeth M Wilson, Andrea Sboner, Young E Whang, Deyou Zheng, Joel S Parker, H Shelton Earp, Gang Greg Wang
Androgen receptor splice variant 7 (AR-V7) is crucial for prostate cancer progression and therapeutic resistance. We show that, independent of ligand, AR-V7 binds both androgen-responsive elements (AREs) and non-canonical sites distinct from full-length AR (AR-FL) targets. Consequently, AR-V7 not only recapitulates AR-FL's partial functions but also regulates an additional gene expression program uniquely via binding to gene promoters rather than ARE enhancers. AR-V7 binding and AR-V7-mediated activation at these unique targets do not require FOXA1 but rely on ZFX and BRD4...
September 11, 2018: Molecular Cell
Yunlu Jia, Monika Hammers-Wirtz, Sarah E Crawford, Qiqing Chen, Thomas-Benjamin Seiler, Andreas Schäffer, Henner Hollert
In the present study, both bioanalytical and instrumental tools were employed to examine the endocrine-disruptive potentials of water samples, cyanobloom samples, and sediment samples collected from in the northern region of Taihu Lake (China) during cyanobloom season. Results from cell-based bioassays suggested the occurrence of estrogenic, anti-estrogenic, anti-androgenic, and anti-glucocorticogenic activities, while no androgenic and glucocorticogenic activities were observed in the collected samples. Using an UPLC-MS/MS system, 29 endocrine disrupting compounds including seven estrogens, seven androgens, six progestogens, and five adrenocortical hormones and four industrial pollutants were simultaneously detected...
September 19, 2018: Science of the Total Environment
Tomonori Kato, Satoko Kojima, Ayumi Fujimoto, Kotaro Otsuka, Takahito Suyama, Kyokushin Hou, Kazuhiro Araki, Hiroshi Masuda, Kazuto Yamazaki, Akira Komiya, Yukio Naya
A 69-year-old man presented initially with back pain and incomplete bilateral lower limb paralysis. The level of prostate-specific antigen (PSA) in the patient was elevated to 167.0 ng/ml, and multiple bone metastases were detected. Thoracic laminectomy was performed in an emergency due to spinal decompression. Subsequently, the patient was diagnosed with prostate cancer from an examination of resected bone specimens. Combined androgen blockade with degarelix and bicalutamide was initiated in October 2013. Consequently, the serum PSA level decreased to <1...
October 2018: Oncology Letters
Matthew P Dent, Hequn Li, Paul L Carmichael, Francis L Martin
This study investigated the use of androgen receptor (AR) reporter gene assay data in a non-animal exposure-led risk assessment in which in vitro anti-androgenic activity and exposure data were put into context using a naturally occurring comparator substance with a history of dietary consumption. First, several dietary components were screened to identify which selectively interfered with AR signaling in vitro, using the AR CALUX® test. The IC50 values from these dose-response data together with measured or predicted human exposure levels were used to calculate exposure:activity ratios (EARs) for the dietary components and a number of other well-known anti-androgenic substances...
September 22, 2018: Toxicological Sciences: An Official Journal of the Society of Toxicology
Shahrzad Rafiei, Bin Gui, Jiaxin Wu, X Shirley Liu, Adam S Kibel, Li Jia
While androgen deprivation therapy (ADT) is an effective treatment for metastatic prostate cancer (mPCa), incurable castration-resistant prostate cancer (CRPC) inevitably develops. Importantly, androgen receptor (AR) continues to be critical for PCa growth and progression after ADT. One of the underlying molecular mechanisms is derepression of AR-repressed genes involved in cell cycle and proliferation after ADT. Here the data demonstrate that C-X-C chemokine receptor type 7 (CXCR7), a seven-transmembrane G-protein-coupled chemokine receptor, is an AR-repressed gene and is upregulated after ADT...
September 17, 2018: Molecular Cancer Research: MCR
Tye E Arbuckle, Amisha Agarwal, Susan H MacPherson, William D Fraser, Sheela Sathyanarayana, Tim Ramsay, Linda Dodds, Gina Muckle, Mandy Fisher, Warren Foster, Mark Walker, Patricia Monnier
BACKGROUND: Anogenital distance (AGD) and the second to fourth finger (2D:4D) digit ratio may be early markers of in utero androgen exposure for the infant. Phthalates and phenols have been identified as endocrine disrupting chemicals. OBJECTIVES: To study the association between prenatal exposure to phthalates, bisphenol A (BPA) and triclosan (TCS) and AGD and the 2D:4D digit ratios. METHODS: Single spot urine samples were collected in the first trimester from the MIREC Study and analyzed for phthalates and phenols...
November 2018: Environment International
Kush Dalal, Helene Morin, Fuqiang Ban, Ashley Shepherd, Michael Fernandez, Kevin J Tam, Huifang Li, Eric LeBlanc, Nathan Lack, Helge Prinz, Paul S Rennie, Artem Cherkasov
The androgen receptor (AR) is a hormone-activated transcription factor that regulates the development and progression of prostate cancer (PCa) and represents one of the most well-established drug targets. Currently clinically approved small molecule inhibitors of AR, such as enzalutamide, are built upon a common chemical scaffold that interacts with the AR by the same mechanism of action. These inhibitors eventually fail due to the emergence of drug-resistance in the form of AR mutations and expression of truncated AR splice variants (e...
September 5, 2018: European Journal of Medicinal Chemistry
Peng Du, Zilei Zhou, Hongmei Huang, Sheng Han, Zeqiong Xu, Ya Bai, Xiqing Li
Phthalate esters (PAEs) are widely used in consumer and industrial products and may thus pose significant health risks. Urine analysis, which has usually been applied to assess the health risks of PAEs, has the drawback of small sample sizes and insufficient representativeness. Wastewater-based epidemiology (WBE) collects wastewater samples containing urine from the entire community and thus is more representative than urine samples. In this work, exposure levels and health risks of PAEs were estimated on a national scale for the first time through the WBE approach...
December 1, 2018: Science of the Total Environment
Guocan Wang, Di Zhao, Denise J Spring, Ronald A DePinho
Despite the high long-term survival in localized prostate cancer, metastatic prostate cancer remains largely incurable even after intensive multimodal therapy. The lethality of advanced disease is driven by the lack of therapeutic regimens capable of generating durable responses in the setting of extreme tumor heterogeneity on the genetic and cell biological levels. Here, we review available prostate cancer model systems, the prostate cancer genome atlas, cellular and functional heterogeneity in the tumor microenvironment, tumor-intrinsic and tumor-extrinsic mechanisms underlying therapeutic resistance, and technological advances focused on disease detection and management...
September 1, 2018: Genes & Development
Feng-Ming Huang, Xiao-Hong Li, Yong Liang
Objective: To investigate the risk factors for early castration-resistant prostate cancer (CRPC) after androgen deprivation therapy (ADT) in patients primarily diagnosed with bone-metastatic prostate cancer (BMPC). METHODS: We retrospectively analyzed the clinical data on 97 cases of primarily diagnosed BMPC treated in our hospital between January 2010 and May 2016. We included the patients without CRPC in group A and those with CRPC found within 12 months after ADT in group B...
August 2018: Zhonghua Nan Ke Xue, National Journal of Andrology
Mizuki Onozawa, Hideyuki Akaza, Shiro Hinotsu, Mototsugu Oya, Osamu Ogawa, Tadaichi Kitamura, Kazuhiro Suzuki, Seiji Naito, Mikio Namiki, Kazuo Nishimura, Yoshihiko Hirao, Taiji Tsukamoto
BACKGROUND: This study investigated how differences in the method of the first-line androgen deprivation therapy (ADT) affected the time to castration-resistant prostate cancer. METHODS: The Japan Study Group of Prostate Cancer compiled a nationwide community-based database on prostate cancer patients who underwent ADT. That database included 13 774 patients who were started on ADT by surgical or medical castration alone (monotherapy group, 5395 cases) or ADT in combination with a nonsteroidal anti-androgen (combined androgen blockade (CAB) group, 8379 cases)...
August 27, 2018: Cancer Medicine
Suzana S Bosanac, Megha Trivedi, Ashley K Clark, Raja K Sivamani, Larissa N Larsen
The role of exogenous progestin in the development of acne is unclear. Progestins are known for their androgenic potential, but newer generations of progestins have low or anti-androgenic activity. This review will evaluate the association between progestins found in hormonal long-acting reversible contraceptives (intrauterine devices and subdermal implants) and acne, as well as the role of oral contraceptives in acne management. Our review demonstrates that the cause and effect relationship between progestins and acne is difficult to establish and future studies that seek to understand how progestins modulate acne are necessary...
May 15, 2018: Dermatology Online Journal
Ching-Yu Lin, Yee-Jee Jan, Li-Kuo Kuo, Bi-Juan Wang, Chieh Huo, Shih Sheng Jiang, Shyh-Chang Chen, Ying-Yu Kuo, Chuang-Rung Chang, Chih-Pin Chuu
Androgen receptor (AR), an androgen-activated transcription factor, belongs to the nuclear receptor superfamily. AR plays an important role in the development and progression of prostate cancer (PCa). However, the role of AR in PCa metastasis is not fully understood. To investigate the role of AR in PCa metastasis, we examined AR expression level in primary and metastatic PCa by analyzing gene array data of 378 primary prostate tumors and 120 metastatic prostate tumors from Oncomine, as well as carrying out immunohistochemical (IHC) staining of 56 prostate cancer samples...
August 24, 2018: Cancer Science
Alec Paschalis, Adam Sharp, Jonathan C Welti, Antje Neeb, Ganesh V Raj, Jun Luo, Stephen R Plymate, Johann S de Bono
Androgen receptor (AR) splice variants (AR-Vs) have been implicated in the development and progression of metastatic prostate cancer. AR-Vs are truncated isoforms of the AR, a subset of which lack a ligand-binding domain and remain constitutively active in the absence of circulating androgens, thus promoting cancer cell proliferation. Consequently, AR-Vs have been proposed to contribute not only to resistance to anti-androgen therapies but also to resistance to radiotherapy in patients receiving combination therapy by promoting DNA repair...
August 22, 2018: Nature Reviews. Clinical Oncology
Gopinath Lakshmana, Aria Baniahmad
The androgen receptor (AR) plays a central role in the pathogenesis of prostate cancer (PCa). Most PCa cases develop eventually from an androgen-dependent stage to castration-resistant prostate cancer (CRPC) with AR-signaling still being active. Thus, inhibition of AR remains a well-established promising drug target in CRPC. However, in spite of the improvements of current treatment for CRPC by targeting the AR, the evolution of adaptive AR-signaling leads to therapy-resistant CRPC. Treatment failure is based mostly on the inability to keep AR under long-term restraint due to adaptive responses of AR-signaling...
August 19, 2018: International Journal of Cancer. Journal International du Cancer
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"